Skip to main content
2024 Annual Meeting Main banner
Final Program


Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Back

Translational Clinical Pharmacology
Symposia

Symposium 13: Advancements in Understanding Drug-induced Hypersensitivity Reactions

Tuesday, September 10, 2024
10:00 AM – 11:30 AM ET
Location:Grand Ballroom D
CE: 1.5

Target Audience:

The target audience for this Symposium is physicians who may encounter patients with drug hypersensitivity reactions in various clinical settings and must understand the multiple mechanisms involved can aid in accurately diagnosing and managing such cases; clinical pharmacologists/pharmacists that are essential in identifying drug interactions and understanding drug pharmacokinetics in relation to hypersensitivity reactions and are also involved in medication management and can provide valuable insights into the implicated drugs and their potential risks and medical researchers (MD/PhD) interested in drug adverse reactions are integral to this Symposium.



Description:

Drug allergy and hypersensitivity reactions present an escalating challenge in healthcare, encompassing a broad spectrum of severity from minor risks to life-threatening outcomes. These reactions can be categorized as immediate or non-immediate based on clinical manifestations and time since drug administration. Immediate reactions manifest within six hours of drug intake, with symptoms emerging within the first hour of treatment. These reactions are characterized by symptoms like urticaria, angioedema, respiratory and gastrointestinal issues, and potentially life-threatening anaphylaxis. In contrast, non-immediate reactions may develop days to weeks after drug exposure to manifest. These reactions involve various skin conditions and, in severe cases, can lead to Stevens-Johnson syndrome or toxic epidermal necrolysis. Despite their significance, standardized diagnostic tools and desensitization protocols remain insufficient. This Symposium aims to address these challenges and establish a new discipline focused on practical clinical approaches to drug allergy and hypersensitivity management. The Symposium will provide comprehensive insights into phenotypes, endotypes, biomarkers and treatment strategies for these reactions. Expert speakers will delve into drug-specific presentations, diagnostics and best practices, including desensitization.

Goals & Objectives:

Following the completion of this activity, the learner will be able to:
  • Explain IgE-mediated immediate drug hypersensitivity reactions (IDHSRs), examining current data and ongoing research on in vivo and in vitro diagnostic tests and their practical application in clinical care;
  • Describe diagnostic challenges and approaches to distinguish IgE from non-IgE IDHSRs, highlighting that most IDHSRs are non-IgE-mediated and misclassification leads to unnecessary drug avoidance and reliance on less safe drugs;
  • Describe severe cutaneous adverse reactions, including the associated phenotypes, clinical aspects, diagnostic criteria, treatments, pharmacogenomics and prevention.

Presentations:

  • Non-IgE-mediated Immediate Drug-induced Hypersensitivity Reactions

    Chair & Faculty: Santiago Alvarez-Arago, MD (he/him/his) – Johns Hopkins Univ School of Medicine

  • IgE-mediated Immediate Drug-induced Hypersensitivity Reactions

    Faculty: Melanie C. Dispenza, MD – Johns Hopkins Univ School of Medicine

  • Drug-induced Severe Cutaneous Adverse Reactions

    Faculty: Elizabeth Phillips, MD – Vanderbilt Univ Medical Ctr

  • Discussion, Questions & Answers, Learner Feedback & Evaluations